Award

75A50124C00033

THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA

About this data

Bounded ingest, not a census: 20,977 contract awards currently loaded (1,294 with full transaction history), per the scope in outlay.config.json. Totals are totals of the ingested set.
Dollar amounts are obligations — money the government has promised to pay, not cash already out the door. Agencies report this data themselves; the Defense Department publishes ~90 days late; the current budget year is still in progress. See methodology.
Source records republish silently; Outlay keeps its own append-only version archive from first pull onward. Post-publication revisions recorded so far: 0 awards (0 revisions). Revisions are routine (spending progresses, errors get corrected) and are not themselves evidence of anything.

Last ingest run #11 (failed) started Aug 5, 2026, 07:42 UTC — 0 awards, 0 details, 0 transactions.

Recipient: BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL
Awarding agency: Department of Health and Human Services
Sub-agency: Office of Assistant Secretary for Preparedness and Response
Fiscal year: FY2024
Obligated (promised): $122,501,232
Total obligation (detail): $122,501,232
Potential value (ceiling): $252,093,994
Outlaid (paid out, linked File C): no linked financial data
Signed: Sep 18, 2024
Period of performance: Sep 30, 2024 – Mar 31, 2032
Competition: FULL AND OPEN COMPETITION
Offers received: 1
Solicitation: NEGOTIATED PROPOSAL/QUOTE
Pricing: COST SHARING
NAICS: 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Award type: DEFINITIVE CONTRACT

Structural flags (2)

Obligations ≥ 3× initial obligation
These contracts grew to at least three times the money they started with, through later changes. Some contracts are planned to grow; others grow past what was originally agreed.
growth_ratio=4.27 · total_obligation=122,501,232 · initial_obligation=28,681,522 · modification_count=5
Rule modification_growth, methodology v1.2.0 — definition and caveats
Competed award, single offer received
These contracts were officially open for any company to compete, but only one company showed up. Sometimes only one company really can do the job; sometimes the contest was set up so only one could win.
extent_competed=A · number_of_offers_received=1
Rule single_bid_competed, methodology v1.2.0 — definition and caveats


0	Sep 18, 2024	—	$28,681,522	THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA
P00001	Oct 10, 2024	OTHER ADMINISTRATIVE ACTION	$0	THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA
P00002	Jul 7, 2025	EXERCISE AN OPTION	$39,113,520	THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA
P00003	Sep 15, 2025	SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE	$24,706,190	THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA - EXECUTE CLIN 0003
P00004	Apr 24, 2026	OTHER ADMINISTRATIVE ACTION	$0	THE PURPOSE OF THIS NO COST MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0001 THROUGH SEPTEMBER 30, 2031, UPDATES ARTICLE V: AGREEMENT ADMINISTRATION, AND ARTICLE VII: OBLIGATION AND PAYMENT, SECTION B.
P00005	Jul 28, 2026	EXERCISE AN OPTION	$30,000,000	THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION 3 CLIN0004 AND UPDATE ATTACHMENT 1: STATEMENT OF WORK DATED JUNE 10, 2026.

Outlay keeps a content-hashed copy of this record from every pull. No post-publication revisions observed so far.